Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165103 | 1.00 | LMNA (0.46) | LMNADPP4DPP9GRM5MAPT | |
| Hydrochloric Acid SCHEMBL27147078 | 0.91 | LMNA (0.40) | LMNADPP4DPP9GRM5MAPT | |
| SCHEMBL29165097 | 0.86 | HSD17B10 (0.52) | LMNAMAPT | |
| SCHEMBL27340981 | 0.86 | HSD17B10 (0.52) | LMNAMAPT | |
| SCHEMBL27152739 | 0.81 | DPP4 (0.50) | DPP4MEN1KMT2A | |
| SCHEMBL29165081 | 0.81 | DPP4 (0.50) | DPP4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30020106 | 0.78 | HSD17B10 (0.43) | LMNAMAPT | |
| SCHEMBL27146221 | 0.76 | CCR4 (0.45) | DPP4DPP9GRM5 | |
| SCHEMBL27146224 | 0.76 | CCR4 (0.45) | DPP4DPP9GRM5 | |
| SCHEMBL632171 | 0.76 | GRM5 (0.59) | LMNADPP4DPP9GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-07-04 | — | — | US | disclosed |
| EP-4326724-A1 | COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2024-02-28 | — | — | EP | disclosed |
| CN-117120443-A | Compounds as adenosine A2a receptor antagonists and pharmaceutical compositions containing the same | 株式会社 钟根堂 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217978-A1 | COMPOUND AS ADENOSINE A2a RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ADORA2A, ADORA1, ADORA2B | LMNA 3812/4885DPP4 2306/4885DPP9 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.